Skip to main content

cefoTEtan (Monograph)

Drug class: Cephamycins
Chemical name: [6R-(6α,7α)]-7-[[[4-(2-Amino-1-carboxy-2-oxoethylidene)-1,3-dithietan-2-yl]carbonyl]amino]-7-methoxy-3-[[(1-methyl-1H-tetrazol-5-yl)thio]methyl]-8-oxo-5-thia-1-azabicyclo-[4.2.0]oct-2-ene-2-carboxylic acid disodium salt
CAS number: 74356-00-6

Medically reviewed by Drugs.com on Sep 25, 2023. Written by ASHP.

Introduction

Antibacterial; β-lactam antibiotic; cephamycin.1 2 3 4 5 26 62 110 157

Uses for cefoTEtan

Bone and Joint Infections

Treatment of bone and joint infections caused by Staphylococcus aureus.1 2 110 157

Gynecologic Infections

Treatment of gynecologic infections caused by susceptible S. aureus (including penicillinase-producing strains), S. epidermidis, Streptococcus agalactiae (group B streptococci), other streptococci (except enterococci), Escherichia coli, Neisseria gonorrhoeae, Proteus mirabilis, Bacteroides (except B. distasonis, B. ovatus, B. thetaiotaomicron), Fusobacterium, and gram-positive anaerobic cocci (including Peptococcus and Peptostreptococcus).1 2 66 110 157

Treatment of pelvic inflammatory disease (PID).344 346 419 Cefotetan (or cefoxitin) in conjunction with doxycycline considered a regimen of choice by CDC and others when a parenteral regimen indicated for treatment of PID.344 346 Because cefotetan (like cephalosporins) is not active against Chlamydia, concomitant use of a drug active against Chlamydia (e.g., doxycycline) is necessary when these organisms are suspected pathogens.1 110 157 344

Intra-abdominal Infections

Treatment of intra-abdominal infections caused by susceptible Streptococcus (except enterococci), E. coli, Klebsiella (including K. pneumoniae), Bacteroides (except B. distasonis, B. ovatus, B. thetaiotaomicron), or Clostridium.1 2 110 157

May be effective for treatment of mild to moderate infections caused by B. fragilis,88 but other anti-infectives (e.g., metronidazole, clindamycin) preferred,88 97 especially for severe or life-threatening infections.88

IDSA states cefotetan not recommended for empiric treatment of intra-abdominal infections because of increasing prevalence of B. fragilis resistant to the drug.161

Respiratory Tract Infections

Treatment of lower respiratory tract infections caused by susceptible S. pneumoniae, S. aureus (including penicillinase-producing strains), Haemophilus influenzae (including ampicillin-resistant strains), E. coli, Klebsiella (including K. pneumoniae), P. mirabilis, or Serratia marcescens.1 2 53 110 157

Skin and Skin Structure Infections

Treatment of skin and skin structure infections caused by susceptible S. aureus (including penicillinase-producing strains), S. epidermidis, S. pyogenes (group A β-hemolytic streptococci), other streptococci (except enterococci), E. coli, K. pneumoniae, Peptococcus niger, or Peptostreptococcus.1 110 157

Urinary Tract Infections (UTIs)

Treatment of UTIs caused by susceptible E. coli, Klebsiella (including K. pneumoniae), P. mirabilis, P. vulgaris, Providencia rettgeri, or Morganella morganii.1 2 51 52 110 157

Should not be used alone for UTIs if Pseudomonas aeruginosa is a possible pathogen since most strains are resistant.2 88

Perioperative Prophylaxis

Perioperative prophylaxis in women undergoing hysterectomy1 2 67 110 157 360 374 or cesarean section.1 2 68 130 149 157 Cefazolin, cefotetan, cefoxitin, or ampicillin and sulbactam usually recommended for women undergoing vaginal, abdominal, or laparoscopic hysterectomy;360 374 cefazolin usually recommended for women undergoing cesarean section.360 374

Perioperative prophylaxis in patients undergoing colorectal or other GI surgery.1 2 69 72 110 157 360 374 Cefoxitin, cefotetan, cefazolin (in conjunction with metronidazole), ampicillin and sulbactam, or ertapenem usually recommended.360 374 Many clinicians recommend using both a parenteral and oral regimen (i.e., neomycin in conjunction with erythromycin or metronidazole and mechanical bowel preparation) for perioperative prophylaxis in patients undergoing colorectal surgery,153 360 374

Perioperative prophylaxis in patients undergoing uncomplicated (nonperforated) appendectomy.360 Cefoxitin, cefotetan, or cefazolin (in conjunction with metronidazole) usually recommended for patients undergoing appendectomy.360

Perioperative prophylaxis in patients undergoing biliary tract surgery.1 2 70 157 360 374 Cefazolin usually recommended for high-risk patients undergoing open biliary tract surgery;360 374 alternatives include cefotetan, cefoxitin, or ampicillin and sulbactam.360 374 Prophylaxis not considered necessary for low-risk patients undergoing elective laparoscopic cholecystectomy.360 374

Has been used for perioperative prophylaxis in patients undergoing transurethral surgery;1 2 71 110 157 not usually recommended for urinary tract surgery.360 374

cefoTEtan Dosage and Administration

Administration

Administer by IV injection1 or infusion1 110 157 or by deep IM injection.1

IV route preferred for treatment of bacteremia, septicemia, or other severe or life-threatening infections and in patients with lowered resistance resulting from debilitating conditions (e.g., malnutrition, trauma, surgery, diabetes, heart failure, malignancy), particularly if shock is present or impending.1 110 157

For solution and drug compatibility information, see Compatibility under Stability.

IV Injection

Reconstitution

Vials containing 1 or 2 g of cefotetan: Reconstitute with 10 or 10–20 mL, respectively, of sterile water for injection to provide solution containing approximately 95 or 95–182 mg/mL, respectively.1 Shake to dissolve; let stand until clear.1

Rate of Administration

Inject appropriate dose of reconstituted solution directly into a vein over a 3- to 5-minute period or slowly into the tubing of a compatible IV solution.1

IV Infusion

IV infusions should preferably be given using butterfly or scalp vein-type needles.1 110 157 Other IV solutions flowing through a common administration tubing or set should be discontinued while cefotetan is infused.1 110 157

Reconstitution

Vials containing 1 or 2 g of cefotetan: Reconstitute with 10 or 10–20 mL, respectively, of sterile water for injection to provide solutions containing approximately 95 or 95–182 mg/mL, respectively.1 Shake to dissolve; let stand until clear.1

Pharmacy bulk package vial containing 10 g of cefotetan: Reconstitute with 50 or 100 mL of sterile water for injection, 5% dextrose injection, or 0.9% sodium chloride injection to provide solution containing approximately 180 or 95 mg/mL, respectively.110 Shake to dissolve; let stand until clear.110 Not intended for direct IV infusion; prior to administration, doses from reconstituted pharmacy bulk package vial must be further diluted in a compatible IV infusion solution within 4 hours.110 Transfer individual doses to a compatible IV solution using suitable sterile transfer device or dispensing set; do not use syringe with needle since leakage could occur.110 Consult manufacturer’s directions for additional information.110

Duplex drug delivery system containing 1 or 2 g of cefotetan powder and 50 mL of 3.58 or 2.08% dextrose injection, respectively, in separate chambers: Reconstitute (activate) according to the manufacturer’s directions.157 If refrigerated after reconstitution (see Storage under Stability), allow solution to reach room temperature prior to administration.157

Rate of Administration

Administer by IV infusion over 20–60 minutes.1 2 52 53 110

IM Administration

Administer IM injections deeply into a large muscle, such as upper outer quadrant of gluteus maximus.1 Use aspiration to ensure needle is not in a blood vessel.1

Reconstitution

Vials containing 1 or 2 g of cefotetan: Prepare IM injections by adding 2 or 3 mL of sterile or bacteriostatic water for injection, 0.9% sodium chloride injection, or 0.5 or 1% lidocaine hydrochloride injection to provide solutions containing approximately 400 or 500 mg/mL, respectively.1 Shake to dissolve; let stand until clear.1

Dosage

Available as cefotetan disodium; dosage expressed in terms of cefotetan.1 110 157

Pediatric Patients

General Pediatric Dosage† [off-label]
Mild to Moderate Infections in Children Beyond Neonatal Period† [off-label]
IV or IM

AAP recommends 60 mg/kg daily given in 2 divided doses.292

Severe Infections in Children Beyond Neonatal Period† [off-label]
IV or IM

AAP recommends 100 mg/kg daily given in 2 divided doses.292

Perioperative Prophylaxis
Colorectal Surgery, Appendectomy (Nonperforated), Biliary Tract, or Other GI Surgery
IV

Children ≥1 year of age† [off-label]: Some clinicians recommend 40 mg/kg given within 1 hour prior to incision.374

If procedure is prolonged >3–4 hours, major blood loss occurs, or other factors are present that shorten drug half-life, additional intraoperative doses may be given.360 374

Duration of prophylaxis should be <24 hours for most procedures;360 374 no evidence to support continuing prophylaxis after wound closure or until all indwelling drains and intravascular catheters are removed.360 374

Adults

General Adult Dosage
Less Severe Infections
IV or IM

1 or 2 g every 12 hours.1 110 157

Severe Infections
IV

2 g every 12 hours.1 110 157

Life-threatening Infections
IV

3 g every 12 hours.1 110 157

Gynecologic Infections
Pelvic Inflammatory Disease (PID)
IV

2 g every 12 hours;344 346 used in conjunction with IV or oral doxycycline (100 mg every 12 hours).344 346

Cefotetan may be discontinued 24–48 hours after clinical improvement occurs and oral doxycycline (100 mg every 12 hours) continued to complete 14 days of treatment.344 346

Skin and Skin Structure Infections
Mild to Moderate Infections
IV

1 g every 12 hours or 2 g every 24 hours.1 110 157 For infections caused by K. pneumoniae, 1 or 2 g every 12 hours.1 110 157

IM

1 g every 12 hours.1 For infections caused by K. pneumoniae, 1 or 2 g every 12 hours.1

Severe Infections
IV

2 g every 12 hours.1 110 157

Urinary Tract Infections (UTIs)
IV or IM

500 mg every 12 hours; 1 or 2 g every 12 hours; or 1 or 2 g every 24 hours.1 110 157

Perioperative Prophylaxis
Gynecologic and Obstetric Surgery
IV

Hysterectomy (vaginal, abdominal, laparoscopic): 1 or 2 g given within 0.5–1 hour prior to incision.1 110 157 360 374

Cesarean section: 1 or 2 g given within 0.5–1 hour prior to incision.1 110 157 360 374 Manufacturers recommend giving dose as soon as umbilical cord is clamped,1 110 157 but there is some evidence that giving dose prior to incision is more effective than after clamping.360 374

If procedure is prolonged >3–4 hours, major blood loss occurs, or other factors are present that shorten drug half-life, additional intraoperative doses may be given (e.g., every 6 hours, measured from time preoperative dose is initiated).360 374

Duration of prophylaxis should be <24 hours for most procedures; no evidence to support continuing prophylaxis after wound closure or until all indwelling drains and intravascular catheters are removed.360 374

Colorectal Surgery, Appendectomy (Nonperforated), Biliary Tract, or Other GI Surgery
IV

1 or 2 g given within 0.5–1 hour prior to incision.1 110 157 360 374

If procedure is prolonged >3–4 hours, major blood loss occurs, or other factors are present that shorten drug half-life, additional intraoperative doses may be given (e.g., every 6 hours, measured from time preoperative dose is initiated).360 374

Duration of prophylaxis should be <24 hours for most procedures; no evidence to support continuing prophylaxis after wound closure or until all indwelling drains and intravascular catheters are removed.360 374

Transurethral Surgery
IV

1 or 2 g given within 0.5–1 hour prior to incision.1 110 157

Prescribing Limits

Adults

Maximum 6 g daily.1 110 157

Special Populations

Renal Impairment

Adults with renal impairment: Dosage adjustments required based on Clcr.1 2 37 39 43 110 157 (See Table 1.)

Table 1. Dosage of Cefotetan for Adults with Renal Impairment139110157

Clcr (mL/min)

Dosage

>30

Usual dose every 12 hours

10–30

Usual dose every 24 hours or 50% of usual dose every 12 hours

<10

Usual dose every 48 hours or 25% of usual dose every 12 hours

Hemodialysis patients

25% of usual dose every 24 hours on days between dialysis and 50% of usual dose on the day of dialysis

Geriatric Patients

Cautious dosage selection because of age-related decreases in renal function.1 110 157 (See Renal Impairment under Dosage and Administration.)

Detailed Cefotetan dosage information

Cautions for cefoTEtan

Contraindications

Warnings/Precautions

Warnings

Superinfection/Clostridium difficile-associated Diarrhea and Colitis

Possible emergence and overgrowth of nonsusceptible bacteria or fungi.1 110 157 Careful observation of patient is essential.1 110 157 Institute appropriate therapy if superinfection occurs.1 110 157

Treatment with anti-infectives alters normal colon flora and may permit overgrowth of Clostridium difficile.1 110 157 302 303 304 C. difficile infection (CDI) and C. difficile-associated diarrhea and colitis (CDAD; also known as antibiotic-associated diarrhea and colitis or pseudomembranous colitis) reported with nearly all anti-infectives, including cefotetan, and may range in severity from mild diarrhea to fatal colitis.1 110 157 302 303 304 C. difficile produces toxins A and B which contribute to development of CDAD;1 110 157 302 hypertoxin producing strains of C. difficile are associated with increased morbidity and mortality since they may be refractory to anti-infectives and colectomy may be required.1 110 157

Consider CDAD if diarrhea develops during or after therapy and manage accordingly.1 110 157 302 303 304 Obtain careful medical history since CDAD may occur as late as ≥2 months after anti-infective therapy is discontinued.1 110 157

If CDAD suspected or confirmed, discontinue anti-infective therapy not directed against C. difficile whenever possible.1 110 157 302 Initiate appropriate supportive therapy (e.g., fluid and electrolyte management, protein supplementation), anti-infective therapy directed against C. difficile (e.g., metronidazole, vancomycin), and surgical evaluation as clinically indicated.1 110 157 302 303 304

Hemolytic Anemia

Severe hemolytic anemia (including fatalities) reported rarely with cefotetan;1 110 114 117 118 119 120 127 157 hemolytic anemia reported in a few women undergoing obstetric and gynecologic procedures who received a single dose for perioperative prophylaxis.127 Similar immune-mediated hemolytic anemia reported with some cephalosporins (e.g., cefotaxime, ceftizoxime [no longer commercially available in the US], ceftriaxone).1 110 146 147 148 157

Periodically monitor for signs and symptoms of hemolytic anemia; assess hematologic parameters when appropriate.1 110 157

If hemolytic anemia develops within 2–3 weeks after initiation of cefotetan, the diagnosis of immune-mediated hemolytic anemia should be considered and the drug discontinued until the etiology of anemia is determined.1 110 157 Consider blood transfusions as needed.1 110 157

Prolonged PT

Prolonged PT (with or without bleeding) reported rarely.1 2 76 77 78 110 131 132 133 157

Monitor PT in patients at risk, including geriatric patients and those with renal or hepatic impairment, malnutrition, or cancer.1 110 132 133 157 Administer vitamin K when indicated.1 76 110 132 133 157

Sensitivity Reactions

Hypersensitivity Reactions

Possible hypersensitivity reactions, including rash (maculopapular or erythematous), pruritus, fever, eosinophilia, urticaria, anaphylaxis, erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis.1 110 157 a

If allergic reaction occurs, discontinue cefotetan and institute appropriate therapy as indicated (e.g., epinephrine, corticosteroids, maintenance of an adequate airway and oxygen).1 110 157

Cross-hypersensitivity

Partial cross-allergenicity among β-lactam antibiotics, including penicillins, cephalosporins, and cephamycins.1 37 60 110 157

Prior to initiation of therapy, make careful inquiry concerning previous hypersensitivity reactions to cefotetan, cephalosporins, penicillins, or other drugs.1 110 157 a Cautious use recommended in individuals hypersensitive to penicillins;1 110 157 a avoid use in those who have had an immediate-type (anaphylactic) hypersensitivity reaction and administer with caution in those who have had a delayed-type (e.g., rash, fever, eosinophilia) reaction.a

General Precautions

History of GI Disease

Use with caution in patients with history of GI disease, particularly colitis.1 110 157 (See Superinfection/Clostridium difficile-associated Diarrhea and Colitis [CDAD] under Cautions.)

Selection and Use of Anti-infectives

To reduce development of drug-resistant bacteria and maintain effectiveness of cefotetan and other antibacterials, use only for treatment or prevention of infections proven or strongly suspected to be caused by susceptible bacteria.1 110 157

When selecting or modifying anti-infective therapy, use results of culture and in vitro susceptibility testing.1 110 157 In the absence of such data, consider local epidemiology and susceptibility patterns when selecting anti-infectives for empiric therapy.1 110 157

In certain serious infections when causative organism is unknown and in cases of confirmed or suspected gram-positive or -negative sepsis, concomitant use of an aminoglycoside may be indicated pending results of in vitro susceptibility tests.1 110 157 (See Aminoglycosides under Interactions.)

Patients with Diabetes

Like other dextrose-containing solutions, use Duplex drug delivery system containing 1 or 2 g of cefotetan powder and 50 mL of 3.58 or 2.08% dextrose injection, respectively, with caution in patients with overt or known subclinical diabetes mellitus or in patients with carbohydrate intolerance for any reason.157

Sodium Content

Contains approximately 80 mg (3.5 mEq) of sodium per g of cefotetan.1 110 157

Specific Populations

Pregnancy

Category B.1 110 157

Lactation

Distributed into milk in low concentrations; use with caution.1 110 157

Pediatric Use

Safety and efficacy not established in children.1 110 157 (See Pediatric Patients under Dosage and Administration.)

Geriatric Use

Safety and efficacy in those ≥60 years of age similar to that in younger adults, but possibility exists of greater sensitivity to the drug in some geriatric patients.1 110 157

Substantially eliminated by kidneys; risk of toxicity may be greater in those with impaired renal function.1 110 157 Select dosage with caution and consider monitoring renal function because of age-related decreases in renal function.1 110 157 (See Renal Impairment under Dosage and Administration.)

Renal Impairment

Decreased clearance and increased half-life.1 110 157

Reduce dosage in those with renal impairment.1 110 157 (See Renal Impairment under Dosage and Administration.)

Common Adverse Effects

GI effects, hematologic effects (eosinophilia, positive direct Coombs test, thrombocytosis), elevated hepatic enzymes, hypersensitivity reactions, local reactions at administration site.1 110 157

Drug Interactions

Specific Drugs and Laboratory Tests

Drug or Test

Interaction

Comments

Alcohol

Possibility of disulfiram-like reactions (flushing, sweating, headache, tachycardia) if alcohol ingested within 72 hours after cefotetan1 2 108 110 157

Avoid ingesting alcohol during and for 72 hours after cefotetan1 2 108 110

Appears to result from accumulation of acetaldehyde2 73 74 75

Aminoglycosides

Possible increased risk of nephrotoxicity1 61 110 157

In vitro evidence of additive or synergistic antibacterial activity against S. aureus and some gram-negative bacilli2 5 17 24 96

Closely monitor renal function if used concomitantly1 110 157

Administer separately; do not admix1 110 157

Probenecid

Concomitant probenecid does not appear to affect pharmacokinetics of cefotetan since the drug is excreted principally by glomerular filtration and nonrenal mechanisms87

Tests for creatinine

High concentrations may cause falsely elevated serum or urine creatinine values when the Jaffe reaction is used1 110 157

Tests for glucose

Possible false-positive reactions in urine glucose tests using Clinitest, Benedict’s solution, or Fehling’s solution1 110 157

Use glucose tests based on enzymatic glucose oxidase reactions (e.g., Clinistix)1 110 157
Cefotetan drug interactions (more detail)

cefoTEtan Pharmacokinetics

Absorption

Bioavailability

Not absorbed from the GI tract; must be given parenterally.46

Appears to be completely absorbed following IM administration;2 41 peak plasma concentrations attained 1.5–4 hours after a dose.2 41 42 64

Distribution

Extent

Widely distributed into body tissues and fluids including gallbladder,2 64 80 skin,1 64 80 110 157 muscle,1 64 80 110 157 fat,1 64 80 110 157 myometrium,1 48 64 110 157 endometrium,1 48 64 79 110 157 fallopian tube,48 64 79 cervix,1 110 157 ovary,1 64 110 157 uterus and adnexa,64 81 prostatic tissue,2 64 kidney,1 64 110 157 ureter,1 64 110 157 bladder,1 64 110 157 maxillary sinus mucosa,1 110 157 tonsils,1 2 64 110 157 sputum,2 64 bile,1 2 37 46 64 110 157 and wound,2 80 prostatic,64 and peritoneal fluids.1 2 49 64 80 110 157

Only low concentrations attained in CSF.2 88

Crosses the placenta1 2 64 81 110 157 and is distributed into milk in low concentrations.1 2 64 110 157

Plasma Protein Binding

76–91%.1 2 5 26 37 38 57 64 110 157

Elimination

Metabolism

Does not appear to be metabolized,1 2 38 110 157 but 1–10% of a dose is present in plasma and urine as a tautomer of the drug.1 2 39 40 45 47 64 82 110 157 This tautomer has microbiologic activity and pharmacokinetics similar to cefotetan.1 39 44 64 82 110 157

Elimination Route

Eliminated principally in urine by glomerular filtration;1 2 37 38 39 40 41 42 47 64 82 110 157 also eliminated by biliary excretion.39 57 64

49–81% of a dose eliminated unchanged in urine;1 2 37 38 39 40 41 42 47 64 82 110 157 approximately 20% excreted in bile.57 64

Half-life

Adults with normal renal function: Distribution half-life 0.2–1.1 hours39 41 45 47 and elimination half-life 2.8–4.6 hours.1 2 37 38 39 41 42 45 47 57 64 82 110 157

Special Populations

Patients with impaired renal function: Renal elimination decreased, serum concentrations increased, and half-life prolonged.1 2 39 43 45 64 110 157 Half-life may be 10 hours in those with moderate renal impairment.1 110 157

Stability

Storage

Parenteral

Powder for Injection or IV Infusion

Vials containing 1 or 2 g of cefotetan: ≤22° C;1 protect from light.1

IV solutions containing 95–182 mg of cefotetan/mL prepared using sterile water are stable for 24 hours at 25°C, 96 hours when refrigerated at 5°C, or at least 1 week when frozen at -20°C.1 64 65

IM solutions containing 400 or 500 mg/mL prepared using sterile or bacteriostatic water, 0.9% sodium chloride, or 0.5 or 1% lidocaine hydrochloride are stable for 24 hours at 25°C, 96 hours when refrigerated at 5°C, or at least 1 week when frozen at -20°C.1 64 Reconstituted solutions transferred to disposable glass or plastic syringes are stable for 24 hours at room temperature or 96 hours when refrigerated.1

Powder and reconstituted solutions may darken to a deeper yellow; does not indicate loss of potency.64 87

Powder for IV Infusion

Pharmacy bulk package vial containing 10 g of cefotetan: 20–25°C;110 protect from light.110 Transfer reconstituted solution and dilute in compatible IV infusion solution within 4 hours after vial originally entered;110 discard any portion of reconstituted pharmacy bulk package not used within 4 hours.110 Following dilution in compatible IV infusion solution, use within 24 hours if stored at room temperature, within 96 hours if refrigerated at 5°C, or within 1 week if frozen.110

Duplex drug delivery system containing 1 or 2 g of cefotetan powder and 50 mL of dextrose injection in separate chambers: 20–25°C (may be exposed to 15–30°C).157 Following reconstitution (activation), use within 12 hours if stored at room temperature or within 5 days if stored in a refrigerator; do not freeze.157

Compatibility

Parenteral

Solution CompatibilityHID

Compatible

Dextrose 5% in water

Sodium chloride 0.9%
Drug Compatibility
Y-site CompatibilityHID

Compatible

Allopurinol sodium

Amifostine

Aztreonam

Bivalirudin

Dexmedetomidine HCl

Diltiazem HCl

Docetaxel

Etoposide phosphate

Famotidine

Fenoldopam mesylate

Filgrastim

Fluconazole

Fludarabine phosphate

Gemcitabine HCl

Granisetron HCl

Heparin sodium

Hetastarch in lactated electrolyte injection (Hextend)

Insulin, regular

Linezolid

Melphalan HCl

Meperidine HCl

Morphine sulfate

Paclitaxel

Palonosetron HCl

Propofol

Remifentanil HCl

Sargramostim

Tacrolimus

Teniposide

Theophylline

Thiotepa

Incompatible

Pemetrexed disodium

Promethazine HCl

Vinorelbine tartrate

Variable

Vancomycin HCl

Actions and Spectrum

Advice to Patients

Preparations

Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.

* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name

cefoTEtan Disodium in Dextrose

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Parenteral

For injection

1 g (of cefotetan)*

Cefotetan Disodium for Injection

2 g (of cefotetan)*

Cefotetan Disodium for Injection

For injection, for IV infusion

1 g (of cefotetan)*

Cefotetan Disodium for Injection (available in dual-chambered Duplex drug delivery system with 3.58% dextrose injection)

B Braun

2 g (of cefotetan)*

Cefotetan Disodium for Injection (available in dual-chambered Duplex drug delivery system with 2.08% dextrose injection)

B Braun

10 g (of cefotetan) pharmacy bulk package*

Cefotetan Disodium for Injection

AHFS DI Essentials™. © Copyright 2024, Selected Revisions October 3, 2014. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.

† Off-label: Use is not currently included in the labeling approved by the US Food and Drug Administration.

References

1. APP Pharmaceuticals, LLC. Cefotetan for injection prescribing information. Schaumburg, IL; 2010 Sep.

2. Ward A, Richards DM. Cefotetan: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs. 1985; 30:382-426. http://www.ncbi.nlm.nih.gov/pubmed/3905336?dopt=AbstractPlus

3. Ayers LW, Jones RN, Barry AL et al. Cefotetan, a new cephamycin: comparison of in vitro antimicrobial activity with other cephems, β-lactamase stability, and preliminary recommendations for disk diffusion testing. Antimicrob Agents Chemother. 1982; 22:859-77. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=185673&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/6983862?dopt=AbstractPlus

4. Philips I, King A, Shannon K et al. Cefotetan: in vitro antibacterial activity and susceptibility to β-lactamases. J Antimicrob Chemother. 1983; 11(Suppl A):1-9. http://www.ncbi.nlm.nih.gov/pubmed/6601650?dopt=AbstractPlus

5. Grassi GG, Alesina R, Ferrara A et al. In-vitro antibacterial activity of cefotetan. J Antimicrob Chemother. 1983; 11(Suppl A):45-58. http://www.ncbi.nlm.nih.gov/pubmed/6573325?dopt=AbstractPlus

6. Grimm H. Susceptibility of bacterial pathogens to cefotetan judged by MIC and disc tests. J Antimicrob Chemother. 1983; 11(Suppl A):37-43. http://www.ncbi.nlm.nih.gov/pubmed/6573324?dopt=AbstractPlus

7. Werner H. Inhibitory activity of cefotetan and other lactams against anaerobes. J Antimicrob Chemother. 1983; 11(Suppl A):107-15. http://www.ncbi.nlm.nih.gov/pubmed/6573311?dopt=AbstractPlus

8. Owens WE, Finegold SM. Comparative in vitro susceptibilities of anaerobic bacteria to cefmenoxime, cefotetan, and N-formimidoyl thienamycin. Antimicrob Agents Chemother. 1983; 23:626-9. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=184715&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/6305265?dopt=AbstractPlus

9. Watt B, Brown FV. The comparative in-vitro activity of cefotetan against anaerobic bacteria. J Antimicrob Chemother. 1985; 15:671-7. http://www.ncbi.nlm.nih.gov/pubmed/3861604?dopt=AbstractPlus

10. Ruckdeschel G. Activity in vitro of cefotetan against non-sporing anaerobes: a comparative study. J Antimicrob Chemother. 1983; 11(Suppl A):117-24. http://www.ncbi.nlm.nih.gov/pubmed/6573312?dopt=AbstractPlus

11. Cocuzza G, Blandino G, Mattina R. Stability of cefotetan to gram-negative β-lactamases. J Antimicrob Chemother. 1983; 11(Suppl A):139-45. http://www.ncbi.nlm.nih.gov/pubmed/6601653?dopt=AbstractPlus

12. Labia R, Morand A, Peduzzi J. Cefotetan and β-lactamases: an unusual property: the inactivation of some β-lactamases by cefotetan. J Antimicrob Chemother. 1983; 11(Suppl A):153-57. http://www.ncbi.nlm.nih.gov/pubmed/6601655?dopt=AbstractPlus

13. Nolan RD, Jude DA. The interactions of [14C] cefotetan with penicillin binding proteins of a wide variety of gram-positive and gram-negative species. J Antimicrob Chemother. 1983; 11(Suppl A):169-77. http://www.ncbi.nlm.nih.gov/pubmed/6573313?dopt=AbstractPlus

14. Hart CA, Percival A. Susceptibilities of gentamicin-resistant gram-negative aerobic bacilli to cefotetan and other β-lactams. J Antimicrob Chemother. 1983; 11(Suppl A):95-101. http://www.ncbi.nlm.nih.gov/pubmed/6573329?dopt=AbstractPlus

15. Clarke AM, Zemcov SJ. Antibacterial activity of the cephamycin cefotetan: an in vitro comparison with other lactam antibiotics. J Antimicrob Chemother. 1983; 11(Suppl A):67-72. http://www.ncbi.nlm.nih.gov/pubmed/6404881?dopt=AbstractPlus

16. Moosdeen F, Maskell J, Philpott-Howard J et al. Cefotetan activity against gram-negative aerobes and anaerobes. J Antimicrob Chemother. 1983; 11(Suppl A):59-65. http://www.ncbi.nlm.nih.gov/pubmed/6601657?dopt=AbstractPlus

17. Bauernfeind A. Cefotetan: profile of in-vitro activity. J Antimicrob Chemother. 1983; 11(Suppl A):19-29. http://www.ncbi.nlm.nih.gov/pubmed/6601656?dopt=AbstractPlus

18. Dette GA, Knothe H, Henckel S. Cefotetan: antimicrobial activity in-vitro compared with that of cefotaxime. J Antimicrob Chemother. 1983; 11(Suppl A):11-7. http://www.ncbi.nlm.nih.gov/pubmed/6302064?dopt=AbstractPlus

19. Minami S, Matsubara N, Yotsuji A et al. Inactivation of cephamycins by various β-lactamases from gram-negative bacteria. J Antibiot. 1984; 38:577-87.

20. Ohm-Smith MJ, Sweet RL, Hadley WK. In vitro activity of cefbuperazone and other antimicrobial agents against isolates from the female genital tract. Antimicrob Agents Chemother. 1985; 27:958-60. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=180195&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/4026268?dopt=AbstractPlus

21. Minami S, Yotsuji A, Inoue M et al. Induction of lactamase by various β-lactam antibiotics in Enterobacter cloacae. Antimicrob Agents Chemother. 1980; 18:382-5. (IDIS 122918)

22. Schell RF, Francisco M, Bihl JA et al. The activity of ceftazidime compared with those of aztreonam, newer cephalosporins and Sch 29482 against nonfermentative gram-negative bacilli. Chemotherapy. 1985; 31:181-90. http://www.ncbi.nlm.nih.gov/pubmed/3888543?dopt=AbstractPlus

23. Sato K, Inoue M, Mitsuhashi S. Activity of β-lactamase produced by Bacteroides fragilis against newly introduced cephalosporins. Antimicrob Agents Chemother. 1980; 17:736-7. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=283862&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/6967295?dopt=AbstractPlus

24. Just HM, Becker C, Bassler M et al. In vitro combination effects of cefotetan with four aminoglycosides, piperacillin and mezlocillin on gram-positive and gram-negative nosocomial bacteria. Chemotherapy. 1984; 30:387-91. http://www.ncbi.nlm.nih.gov/pubmed/6596165?dopt=AbstractPlus

25. Kesado T, Watanabe K, Asahi Y et al. Comparative antibacterial activities of 7α-methoxy cephalosporins and 7β-methoxyiminoacetamido cephalosporins against Bacteroides fragilis. Antimicrob Agents Chemother. 1984; 25:131-3. (IDIS 181532)

26. Wise R, Andrews JM, Hancox J. In vitro activity of cefotetan, a new cephamycin derivative, compared with that of other β-lactam compounds. Antimicrob Agents Chemother. 1982; 21:486-91. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=181919&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/6954875?dopt=AbstractPlus

27. Del Bene VE, Carek PJ, Twitty JA et al. In vitro activity of cefbuperazone compared with that of other new β-lactam agents against anaerobic gram-negative bacilli and contribution of β-lactamase to resistance. Antimicrob Agents Chemother. 1985; 27:817-20. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=180158&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/3874597?dopt=AbstractPlus

28. Hornstein MJ, Jupeau AM, Scavizzi MR et al. In vitro susceptibilities of 126 clinical isolates of Yersinia enterocolitica to 21 β-lactam antibiotics. Antimicrob Agents Chemother. 1985; 27:806-11. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=180156&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/2990327?dopt=AbstractPlus

29. Kesado T, Watanabe K, Asahi Y et al. Susceptibilities of anaerobic bacteria to N-formimidoyl thienamycin (MK0787) and to other antibiotics. Antimicrob Agents Chemother. 1982; 21:1016-22. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=182066&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/6956247?dopt=AbstractPlus

30. Aldridge KE, Sanders CV, Janney A et al. Comparison of the activities of penicillin G and new β-lactam antibiotics against clinical isolates of Bacteroides species. Antimicrob Agents Chemother. 1984; 26:410-3. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=176181&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/6334491?dopt=AbstractPlus

31. Goldstein EJ, Citron DM. Susceptibility of Eikenella corrodens to penicillin, apalcillin, and twelve new cephalosporins. Antimicrob Agents Chemother. 1984; 26:947-8. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=180060&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/6395802?dopt=AbstractPlus

32. Denys GA, Jerris RC, Swenson JM et al. Susceptibility of Propionibacterium acnes clinical isolates to 22 antimicrobial agents. Antimicrob Agents Chemother. 1983; 23:335-7. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=186050&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/6838191?dopt=AbstractPlus

33. Ruckdeschel G, Ehret W, Ahl A. Susceptibility of Legionella spp. to imipenem and 27 other beta-lactam antibiotics. Eur J Clin Microbiol. 1984; 3:463-7. http://www.ncbi.nlm.nih.gov/pubmed/6594234?dopt=AbstractPlus

34. Saito H, Sato K, Jin BW. Activities of cefoxitin and cefotetan against Mycobacterium fortuitum infections in mice. Antimicrob Agents Chemother. 1984; 26:270-1. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=284136&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/6592999?dopt=AbstractPlus

35. Cynamon MH, Palmer GS. In vitro susceptibility of Mycobacterium fortuitum to N-formimidoyl thienamycin and several cephamycins. Antimicrob Agents Chemother. 1982; 22:1079-81. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=185727&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/6961887?dopt=AbstractPlus

36. Hart CA, Percival A. Resistance to cephalosporins among gentamicin-resistant Klebsiellae. J Antimicrob Chemother. 1982; 9:275-86. (IDIS 175362)

37. Balant L, Dayer P, Auckenthaler R. Clinical pharmacokinetics of the third generation cephalosporins. Clin Pharmacokinet. 1985; 10:101-43. http://www.ncbi.nlm.nih.gov/pubmed/3888488?dopt=AbstractPlus

38. Yates RA, Adam HK, Donnelly RJ et al. Pharmacokinetics and tolerance of single intravenous doses of cefotetan disodium in male caucasian volunteers. J Antimicrob Chemother. 1983; 11(Suppl A):185-91. http://www.ncbi.nlm.nih.gov/pubmed/6573315?dopt=AbstractPlus

39. Smith BR, LeFrock JL, Thyrum PT et al. Cefotetan pharmacokinetics in volunteers with various degrees of renal function. Antimicrob Agents Chemother. 1986; 29:887-93. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=284173&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/3460524?dopt=AbstractPlus

40. Adam HK, Houghton HL, Yates RA et al. Pharmacokinetics and tolerance of a 24-h infusion of cefotetan disodium (with and without loading dose) in normal caucasian volunteers. J Antimicrob Chemother. 1983; 11(Suppl A):193-9. http://www.ncbi.nlm.nih.gov/pubmed/6573316?dopt=AbstractPlus

41. Guibert J, Kitzis MD, Yvelin C et al. Pharmacokinetics of single intravenous and intramuscular doses of cefotetan in normal human volunteers. J Antimicrob Chemother. 1983; 11(Suppl A):201-6. http://www.ncbi.nlm.nih.gov/pubmed/6573317?dopt=AbstractPlus

42. Yates RA, Cockshott ID, Houghton HL et al. Pharmacokinetics and tolerance of single intramuscular doses of cefotetan in normal caucasian volunteers. J Antimicrob Chemother. 1983; 11(Suppl A):207-12. http://www.ncbi.nlm.nih.gov/pubmed/6573318?dopt=AbstractPlus

43. Wright N, Wise R, Hegarty T. Cefotetan elimination in patients with varying degrees of renal dysfunction. J Antimicrob Chemother. 1983; 11(Suppl A):213-6. http://www.ncbi.nlm.nih.gov/pubmed/6573319?dopt=AbstractPlus

44. Kees F, Grobecker H. High-performance liquid chromatographic analysis of cefotetan epimers in human plasma and urine. J Chromatogr. 1984; 305:363-71. http://www.ncbi.nlm.nih.gov/pubmed/6584433?dopt=AbstractPlus

45. Ohkawa M, Hirano S, Tokunaga S et al. Pharmacokinetics of cefotetan in normal subjects and patients with impaired renal function. Antimicrob Agents Chemother. 1983; 23:31-5. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=184611&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/6572490?dopt=AbstractPlus

46. Owen AW, Manson JM, Yates RA et al. The pharmacokinetics of cefotetan excretion in the unobstructed biliary tree. J Antimicrob Chemother. 1983; 11(Suppl A):217-21. http://www.ncbi.nlm.nih.gov/pubmed/6573320?dopt=AbstractPlus

47. Nakagawa K, Koyama M, Tachibana A et al. Pharmacokinetics of cefotetan (YMO9330) in humans. Antimicrob Agents Chemother. 1982; 22:935-41. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=185696&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/6961888?dopt=AbstractPlus

48. Just HM, Petersen EE, Bassler M et al. Penetration of cefotetan into serum, myometrium, endometrium and salpinges. Chemotherapy. 1984; 30:305-7. http://www.ncbi.nlm.nih.gov/pubmed/6593163?dopt=AbstractPlus

49. Wise R, Donovan IA, Drumm J et al. Intraperitoneal penetration of cefotetan. Antimicrob Agents Chemother. 1983; 24:279-81. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=185152&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/6579881?dopt=AbstractPlus

50. Ambrose NS, Johnson M, Burdon DW et al. The influence of single dose intravenous antibiotics on faecal flora and emergence of Clostridium difficile. J Antimicrob Chemother. 1985; 15:319-26.

51. Hautmann R, Pranada F, Pusztai-Markos ZS. Cefotetan in complicated urinary tract infections: clinical experience. J Antimicrob Chemother. 1983; 11(Suppl A):223-6.

52. Cox CE, Childs SJ, Wells WG et al. Preliminary report on a comparative trial of cefotetan and cefoxitin in the treatment of urinary tract infections. J Antimicrob Chemother. 1983; 11(Suppl A):227-32. http://www.ncbi.nlm.nih.gov/pubmed/6341350?dopt=AbstractPlus

53. Nolen TM, Phillips HL, Hall HJ. Clinical evaluation of cefotetan in the treatment of lower respiratory tract infections. J Antimicrob Chemother. 1983; 11(Suppl A):233-6. http://www.ncbi.nlm.nih.gov/pubmed/6573322?dopt=AbstractPlus

55. Wise R, Dent J. Stability of β-lactam antibiotics containing N-methylthiotetrazole side-chain. Lancet. 1983; 2:624-5. http://www.ncbi.nlm.nih.gov/pubmed/6136772?dopt=AbstractPlus

56. Smith BR. Effect of storage temperature and time on stability of cefmenoxime, ceftriaxone, and cefotetan in 5% dextrose injection. Am J Hosp Pharm. 1983; 40:1024-5. http://www.ncbi.nlm.nih.gov/pubmed/6307045?dopt=AbstractPlus

57. Harding SM. Pharmacokinetics of the third-generation cephalosporins. Am J Med. 1985; 79(Suppl 2A):21-4. http://www.ncbi.nlm.nih.gov/pubmed/4025382?dopt=AbstractPlus

58. Ettlin R, Hoigne R, Bruppacher R et al. Atopy and adverse drug reactions. Int Arch Allergy Appl Immunol. 1981; 66(Suppl 1):93-5.

59. Patterson R. Allergic reactions to drugs and biological agents. JAMA. 1982; 248:2637-45. http://www.ncbi.nlm.nih.gov/pubmed/7143626?dopt=AbstractPlus

60. Hoigne R, Hopf B, Sonntag R. Penicillins, cephalosporins and tetracyclines. In: Dukes MNG, ed. Meyler’s side effects of drugs. 9th ed. New York: Elsevier/North Holland Inc; 1980:411-22.

61. Mannion JC, Bloch R, Popovich NG. Cephalosporin-aminoglycoside synergistic nephrotoxicity: fact or fiction? Drug Intell Clin Pharm. 1981; 15:248-56.

62. Sanders CC, Sanders WE. The cephalosporins and cephamycins. In: Peterson PK, Verhoef J, eds. The antimicrobial agents annual/1. New York: Elsevier Science Publishers B.V.; 1986:66-90.

64. Stuart Pharmaceuticals. Product monograph on Cefotan (cefotetan disodium). Wilmington, DE; 1986 Mar.

65. Stuart Pharmaceuticals. Product information form on Cefotan (cefotetan disodium). Wilmington, DE; 1984 May.

66. Poindexter AN, Sweet R, Ritter M. Cefotetan in the treatment of obstetric and gynecologic infections. Am J Obstet Gynecol. 1986; 154:946-50. http://www.ncbi.nlm.nih.gov/pubmed/3515949?dopt=AbstractPlus

67. Orr JW, Varner RE, Kilgore LC et al. Cefotetan versus cefoxitin as prophylaxis in hysterectomy. Am J Obstet Gynecol. 1986; 154:960-3. http://www.ncbi.nlm.nih.gov/pubmed/3515952?dopt=AbstractPlus

68. McGregor JA, French JI, Makowski E. Single-dose cefotetan versus multidose cefoxitin for prophylaxis in cesarean section in high-risk patients. Am J Obstet Gynecol. 1986; 154:955-60. http://www.ncbi.nlm.nih.gov/pubmed/3515951?dopt=AbstractPlus

69. Leaper DJ, Cooper MJ, Turner A. A comparative trial of cefotetan and cephazolin for wound sepsis prophylaxis during elective upper GI surgery. In: Lode H, Periti P, Strachan CJ, eds. Cefotetan a long-acting antibiotic for polymicrobial infections. Great Britain: Churchill Livingstone; 1985:263-8.

70. Royston CM, Leighton I, Wale RJ. Prophylaxis in biliary surgery: a comparison of cefotetan and cephazolin. In: Lode H, Periti P, Strachan CJ, eds. Cefotetan a long-acting antibiotic for polymicrobial infections. Great Britain: Churchill Livingstone; 1985:269-73.

71. Dorflinger T, Madsen RE, Madsen PO. A comparison of cefotetan and cefotaxime for prophylaxis in transurethral surgery. In: Lode H, Periti P, Strachan CJ, eds. Cefotetan a long-acting antibiotic for polymicrobial infections. Great Britain: Churchill Livingstone; 1985:284-8.

72. Periti P, Tonelli F. Preliminary results of a prospective multicenter randomized trial of short-term antimicrobial chemoprophylaxis in colorectal surgery. In: Kobayashi H, Lode H, Quintiliani R, eds. Progress in the treatment and prevention of polymicrobial infections: proceedings of a workshop held at the 14th International Congress of Chemotherapy, Kyoto, 1985. Tokyo: University of Tokyo Press; 1986:51-9.

73. Hansten PD. Drug interactions. 5th ed. Philadelphia: Lea & Febiger; 1985:204.

74. Mangini RJ, ed. Drug interaction facts. St. Louis: JB Lippincott Co; 1984(Jul):245.

75. Witt LG, Witt LD. Cephalosporins and ethanol. Drug Interact Newsl. 1983; 3:27-30.

76. Andrassy K, Koderisch J, Bechtold H et al. Haemostasis during treatment with cefotetan. In: Lode H, Periti P, Strachan CJ, eds. Cefotetan a long-acting antibiotic for polymicrobial infections. Great Britain: Churchill Livingstone; 1985:131-7.

77. Machin SJ, Bowcock S, Mackie IF et al. Haemostatic parameters: pilot study with cefotetan compared with other antibiotics. In: Lode H, Periti P, Strachan CJ, eds. Cefotetan a long-acting antibiotic for polymicrobial infections. Great Britain: Churchill Livingstone; 1985:138-42.

78. Triger DR. Coagulation and platelet function in patients with impaired liver function receiving cefotetan. In: Lode H, Periti P, Strachan CJ, eds. Cefotetan a long-acting antibiotic for polymicrobial infections. Great Britain: Churchill Livingstone; 1985:143-6.

79. Daschner FD, Just HM, Peterson EE et al. Penetration of cefotetan into the tissues of the female genital tract. In: Lode H, Periti P, Strachan CJ, eds. Cefotetan a long-acting antibiotic for polymicrobial infections. Great Britain: Churchill Livingstone; 1985:110-2.

80. Wittke RR, Adam D, Keems J. Cefotetan in the treatment and prophylaxis of surgical infections: pharmacokinetics in wound secretion, bile and tissues. In: Lode H, Periti P, Strachan CJ, eds. Cefotetan a long-acting antibiotic for polymicrobial infections. Great Britain: Churchill Livingstone; 1985:255-62.

81. Motomura R, Teramoto C, Souda Y et al. Fundamental and clinical study of cefotetan (YMO9330) in the field of obstetrics and gynecology. Chemotherapy (Tokyo). 1982; 30(Suppl 1):887.

82. Naber K, Kees F, Meyer GP et al. Comparative pharmacokinetic study of cefotetan and cefotaxime in healthy volunteers. In: Lode H, Periti P, Strachan CJ, eds. Cefotetan a long-acting antibiotic for polymicrobial infections. Great Britain: Churchill Livingstone; 1985:88-97.

83. Mondorf AW, Klein S, Weise M. Evaluation of cefotetan in a volunteer study of kidney function. In: Lode H, Periti P, Strachan CJ, eds. Cefotetan a long-acting antibiotic for polymicrobial infections. Great Britain: Churchill Livingstone; 1985:117-21.

84. Murgatroyd LB, Goonetilleke UR, Moseley MJ et al. Cefotetan, a new long-acting cephamycin antibiotic: an interaction study with gentamicin to examine the effects on the kidney. In: Lode H, Periti P, Strachan CJ, eds. Cefotetan a long-acting antibiotic for polymicrobial infections. Great Britain: Churchill Livingstone; 1985:122-30.

85. Daschner FD, Goerke C, Bassler M et al. In vitro comparison of cefotetan with five other cephalosporins against nosocomial pathogens. Chemotherapy. 1982; 28:351-4. http://www.ncbi.nlm.nih.gov/pubmed/6958416?dopt=AbstractPlus

86. Food and Drug Administration. Antibiotic drug; sterile cefotetan disodium. [Docket No. 86N-0191] Fed Regist. 1986; 107:20262-4.

87. Best WE (Stuart Pharmaceuticals, Wilmington, DE): Personal communication; 1986 Aug.

88. Reviewers’ comments (personal observations); 1986 Aug.

89. Stuart Pharmaceuticals. Technical laboratory manual on Cefotan (cefotetan disodium). Wilmington, DE; 1986.

90. Browning M, Chapman S, Cockshott ID et al. Pharmacokinetics of cefotetan in patients requiring continuous ambulatory peritoneal dialysis. In: Lode H, Periti P, Strachan CJ, eds. Cefotetan a long-acting antibiotic for polymicrobial infections. Great Britain: Churchill Livingstone; 1985:106-9.

91. Curtis NA, Eisenstadt RL, Rudd C et al. Inducible type I β-lactamases of gram-negative bacteria and resistance to β-lactam antibiotics. J Antimicrob Chemother. 1986; 17:51-61. http://www.ncbi.nlm.nih.gov/pubmed/3485092?dopt=AbstractPlus

95. Norrby SR. Adverse reactions and interactions with newer cephalosporin and cephamycin antibiotics. Med Toxicol. 1986; 1:32-46. http://www.ncbi.nlm.nih.gov/pubmed/3537614?dopt=AbstractPlus

96. Serra P, Santini C, Micozzi A et al. Cefotetan and amikacin against gram-negative bacilli; in vitro comparative study with other antibiotics and evaluation of their combined activity. Abstracts of the 4th Mediterranean Congress of Chemotherapy. Rhodes, Greece; 1984 Oct 19–24. Abstract No. 226, p. 58.

97. Anon. Choice of antibacterial drugs. Med Lett Treat Guid. 2007; 5:33-50.

98. Youssef RZ, Murray M, Holmes B et al. Cefotetan therapy for gonococcal urethritis and cervicitis. Sex Transm Dis. 1990; 17:99-101. http://www.ncbi.nlm.nih.gov/pubmed/2360135?dopt=AbstractPlus

108. Kline SS, Mauro VF, Forney RB et al. Cefotetan-induced disulfiram-type reactions and hypoprothrombinemia. Antimicrob Agents Chemother. 1987; 31:1328-31. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=174936&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/3479045?dopt=AbstractPlus

109. Bloomberg RJ. Cefotetan-induced anaphylaxis. Am J Obstet Gynecol. 1988; 159:125-6. http://www.ncbi.nlm.nih.gov/pubmed/3164980?dopt=AbstractPlus

110. APP Pharmaceuticals, LLC. Cefotetan for injection pharmacy bulk package prescribing information. Schaumburg, IL; 2011 Nov.

111. Hemsell DL, Wendel GD, Gall SA et al. Multicenter comparison of cefotetan and cefoxitin in the treatment of acute obstetric and gynecologic infections. Am J Obstet Gynecol. 1998; 158:722-7.

114. Wagner BKJ, Heaton AH, Flink JR. Cefotetan disodium-induced hemolytic anemia. Ann Pharmacother. 1992; 26:199-200. http://www.ncbi.nlm.nih.gov/pubmed/1554932?dopt=AbstractPlus

115. Nguyen VD, Nagelberg H, Agarwal BN. Acute interstitial nephritis associated with cefotetan therapy. Am J Kidney Dis. 1990; 16:259-61. http://www.ncbi.nlm.nih.gov/pubmed/2399919?dopt=AbstractPlus

116. Morris JT, McAllister CK. Cefotetan-induced singultus. Ann Intern Med. 1992; 116:522-3. http://www.ncbi.nlm.nih.gov/pubmed/1739250?dopt=AbstractPlus

117. Chenoweth CE, Judd WJ, Steiner EA et al. Cefotetan-induced immune hemolytic anemia. Clin Infect Dis. 1992; 15:863-5. http://www.ncbi.nlm.nih.gov/pubmed/1445986?dopt=AbstractPlus

118. Ehmann WC. Cephalosporin-induced hemolysis: a case report and review of the literature. Am J Hematol. 1992; 40:121-5. http://www.ncbi.nlm.nih.gov/pubmed/1585910?dopt=AbstractPlus

119. Garratty G, Nance S, Lloyd M et al. Fatal immune hemolytic anemia due to cefotetan. Transfusion. 1992; 32:269-71. http://www.ncbi.nlm.nih.gov/pubmed/1557811?dopt=AbstractPlus

120. Gallagher NI, Schergen AK, Sokol-Anderson ML et al. Severe immune-mediated hemolytic anemia secondary to treatment with cefotetan. Transfusion. 1992; 32:202-4. http://www.ncbi.nlm.nih.gov/pubmed/1557799?dopt=AbstractPlus

122. Baxter Healthcare Corporation. Descriptive information on premixed products. Deerfield, IL; 1994 Feb 21.

123. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: Twenty-first informational supplement. CLSI document M100-S21. Wayne, PA; 2011.

126. Eli Lilly & Company. Mandol (cefamandole naftate) for injection prescribing information. In: Physicians’ desk reference. 52nd ed. Montvale, NJ: Medical Economics Company Inc; 1998:1388-90.

127. Garratty G, Leger RM, Arndt PA. Severe immune hemolytic anemia associated with prophylactic use of cefotetan in obstetric and gynecologic procedures. Am J Obstet Gynecol. 1999; 181:103-4. http://www.ncbi.nlm.nih.gov/pubmed/10411803?dopt=AbstractPlus

128. Pfizer. Cefobid (cefoperazone) for intravenous or intramuscular use prescribing information. New York, NY; 2006 Jan.

129. Scott SD, Karran SJ. Cefotetan in the treatment of serious intra-abdominal sepsis: a controlled clinical trial. Int J Clin Pharmacol Res. 1987; 8:229-31.

130. Faro S, Martens MG, Hammill HA et al. Antibiotic prophylaxis: is there a difference? Am J Obstet Gynecol. 1990; 162:900-9.

131. Conjura A, Bell W, Lipsky JJ. Cefotetan and hypoprothrombinemia. Ann Intern Med. 1988; 108:643-4. http://www.ncbi.nlm.nih.gov/pubmed/3162358?dopt=AbstractPlus

132. Sieradzan RR, Bottner WA, Fasco MJ et al. Comparative effects of cefoxitin and cefotetan on vitamin K metabolism. Antimicrob Agents Chemother. 1998; 32:1446-9.

133. Wurtz RM, Sande MA. Cefotetan and coagulopathy. J Infect Dis. 1989; 160:555-6. http://www.ncbi.nlm.nih.gov/pubmed/2760507?dopt=AbstractPlus

134. Kishiyama JL, Adelman DC. The cross-reactivity and immunology of β-lactam antibiotics. Drug Saf. 1994; 10:318-27. http://www.ncbi.nlm.nih.gov/pubmed/8018304?dopt=AbstractPlus

135. Breen GA, St Peter WL. Hypoprothrombinemia associated with cefmetazole. Ann Pharmacother. 1997; 31:180-4. http://www.ncbi.nlm.nih.gov/pubmed/9034420?dopt=AbstractPlus

136. Thompson JW, Jacobs RF. Adverse effects of newer cephalosporins: an update. Drug Saf. 1993; 132-42.

137. Grimes DA, Bount JH, Patrick J et al. Antibiotic treatment of pelvic inflammatory disease: trends among private physicians in the United States, 1996 through 1983. JAMA. 1986; 256:3223-6. http://www.ncbi.nlm.nih.gov/pubmed/3783865?dopt=AbstractPlus

146. Shammo JM, Calhoun B, Mauer AM et al. First two cases of immune hemolytic anemia associated with ceftizoxime. Transfusion. 1999; 39:838-44. http://www.ncbi.nlm.nih.gov/pubmed/10504119?dopt=AbstractPlus

147. Moallem HJ, Garratty G, Wakeham M et al. Ceftriaxone-related fatal hemolysis in an adolescent with perinatally acquired human immunodeficiency virus infection. J Pediatr. 1998; 133:279-81. http://www.ncbi.nlm.nih.gov/pubmed/9709722?dopt=AbstractPlus

148. Shulman IA, Arndt PA, McGehee W et al. Cefotaxime-induced immune hemolytic anemia due to antibodies reacting in vitro by more than one mechanism. Transfusion. 1990; 30:263-6. http://www.ncbi.nlm.nih.gov/pubmed/2316002?dopt=AbstractPlus

149. Noyes N, Berkeley AS, Freedman K et al. Incidence of postpartum endomyometritis following single-dose antibiotic prophylaxis with either ampicillin/sulbactam, cefazolin, or cefotetan in high-risk cesarean section patients. Infect Dis Obstet Gynecol. 1998; 6:220-3. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1784814&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/9894177?dopt=AbstractPlus

150. Sawaya GF, Grady D, Kerlikowske K et al. Antibiotics at the time of induced abortion: the case for universal prophylaxis based on a meta-analysis. Obstet Gynecol. 1996; 87:884-90. http://www.ncbi.nlm.nih.gov/pubmed/8677129?dopt=AbstractPlus

151. Schoetz DJ, Roberts PL, Murray JJ et al. Addition of parenteral cefoxitin to regimen of oral antibiotics for elective colorectal operations. A randomized prospective study. Ann Surg. 1990; 212:209-12. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1358059&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/2100983?dopt=AbstractPlus

153. Nichols RL, Smith JW, Garcia RY et al. Current practices of preoperative bowel preparation among North American colorectal surgeons. Clin Infect Dis. 1997; 24:609-19. http://www.ncbi.nlm.nih.gov/pubmed/9145734?dopt=AbstractPlus

157. B. Braun Medical Inc. Cefotetan for injection and dextrose injection (1 g and 2 g in Duplex container) prescribing information. Irvine, CA; 2012 Aug.

158. Lewis RT. Oral versus systemic antibiotic prophylaxis in elective colon surgery: a randomized study and meta-analysis send a message from the 1990s. Can J Surg. 2002; 45:173-80. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=3686946&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/12067168?dopt=AbstractPlus

159. Espin-Basany E, Sanchez-Garcia JL, Lopez-Cano M et al. Prospective, randomized study on antibiotic prophylaxis in colorectal surgery. Is it really necessary to use oral antibiotics? Int J Colorectal Dis. 2005; 20:542-6.

160. Wren SM, Ahmed N, Jamal A et al. Preoperative oral antibiotics in colorectal surgery increase the rate of Clostridium difficile colitis. Arch Surg. 2005; 140:752-6. http://www.ncbi.nlm.nih.gov/pubmed/16103284?dopt=AbstractPlus

161. Solomkin JS, Mazuski JE, Bradley JS et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis. 2010; 50:133-64. http://www.ncbi.nlm.nih.gov/pubmed/20034345?dopt=AbstractPlus

292. American Academy of Pediatrics. Red Book: 2012 Report of the Committee on Infectious Diseases. 29th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2012.

302. Cohen SH, Gerding DN, Johnson S et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol. 2010; 31:431-55. http://www.ncbi.nlm.nih.gov/pubmed/20307191?dopt=AbstractPlus

303. Fekety R for the American College of Gastroenterology Practice Parameters Committee. Guidelines for the diagnosis and management of Clostridium difficile-associated diarrhea and colitis. Am J Gastroenterol. 1997; 92:739-50. http://www.ncbi.nlm.nih.gov/pubmed/9149180?dopt=AbstractPlus

304. American Society of Health-System Pharmacists Commission on Therapeutics. ASHP therapeutic position statement on the preferential use of metronidazole for the treatment of Clostridium difficile-associated disease. Am J Health-Syst Pharm. 1998; 55:1407-11. http://www.ncbi.nlm.nih.gov/pubmed/9659970?dopt=AbstractPlus

344. Workowski KA, Berman S, Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep. 2010; 59(RR-12):1-110.

346. Anon. Drugs for sexually transmitted infections. Treat Guidel Med Lett. 2010; 8:53-60. http://www.ncbi.nlm.nih.gov/pubmed/20585282?dopt=AbstractPlus

360. . Antimicrobial prophylaxis for surgery. Treat Guidel Med Lett. 2012; 10:73-8; quiz 79-80. http://www.ncbi.nlm.nih.gov/pubmed/22996382?dopt=AbstractPlus

374. Bratzler DW, Dellinger EP, Olsen KM et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery. Am J Health Syst Pharm. 2013; 70:195-283. http://www.ncbi.nlm.nih.gov/pubmed/23327981?dopt=AbstractPlus

417. Cunha BA. Treatment of pelvic inflammatory disease. Clin Pharm. 1990; 9:275-85. http://www.ncbi.nlm.nih.gov/pubmed/2184973?dopt=AbstractPlus

418. Walker CK, Kahn JG, Washington AE et al. Pelvic inflammatory disease: metaanalysis of antimicrobial regimen efficacy. J Infect Dis. 1993; 168:969-78. http://www.ncbi.nlm.nih.gov/pubmed/8376843?dopt=AbstractPlus

419. Hemsell DL, Little BB, Faro S et al. Comparison of three regimens recommended by the Centers for Disease Control and Prevention for the treatment of women hospitalized with acute pelvic inflammatory disease. Clin Infect Dis. 1994; 19:720-7. http://www.ncbi.nlm.nih.gov/pubmed/7803638?dopt=AbstractPlus

a. AHFS Drug Information 2009. McEvoy GK, ed. Cephalosporins General Statement. Bethesda, MD: American Society of Health-System Pharmacists; 2009:93-109.

HID. Trissel LA. Handbook on injectable drugs. 17th ed. Bethesda, MD: American Society of Health-System Pharmacists; 2013:218-21.

Medical Disclaimer